Results 301 to 310 of about 9,590,921 (389)

Population pharmacokinetics and exposure–response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study

British Journal of Clinical Pharmacology, EarlyView.
Aims In the AEGEAN study, perioperative durvalumab plus platinum‐based neoadjuvant chemotherapy for patients with resectable stage II to IIIB (N2) non‐small‐cell lung cancer (NSCLC) demonstrated a favourable benefit–risk profile. This study evaluated population pharmacokinetics (PopPK) and exposure–response (ER) relationships of durvalumab in patients ...
Xiaoying Zhao, Junjie Ding, Jiajia Zhao, Ling Zhang, Aburough Abegesah, Yu‐qian Zhang, Cathy O'Brien, Gary J. Doherty, Allen C. Chen, KyoungSoo Lim, Song Ren, Peiming Ma, Diansong Zhou   +12 more
wiley   +1 more source

Use of SpyGlass™ DS II Direct Visualization System With SpyBite™ Max Forceps for the Removal of Echinococcus Granulosus Causing Biliary Obstruction. [PDF]

ACG Case Rep J
Lanke G, Onkendi E, Arif D, Holder A, Das K.   +4 more
europepmc   +1 more source

Complications of liver transplantation [PDF]

, 1987
Bronsther, OL, Esquivel, CO, Gordon, RD, Iwatsuki, S, Lerut, JP, Makowka, L, Starzl, TE   +6 more
core  

Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aim The benzoxaborole derivative DNDI‐6148 is an antiparasitic agent with activity against multiple Leishmania protozoan species, including L. infantum and L. donovani, which cause visceral leishmaniasis. We investigated the safety, tolerability and pharmacokinetics of single oral doses of DNDI‐6148 in a randomized, parallel‐group, placebo‐controlled ...
Jean‐Yves Gillon, Sophie Delhomme, Delphine Launay, Séverine Blesson, Stéphanie Braillard, Pegah Maghdooni, Frauke Assmus, Richard Hoglund, Joel Tarning, Sabrina Loyau, Byron Arana, Mathilde Latreille‐Barbier, Yves Donazzolo   +12 more
wiley   +1 more source

Biliary Reconstruction in Liver Transplantation with Primary Sclerosing Cholangitis: Roux-en-Y Hepaticojejunostomy or Duct-to-Duct Anastomosis? [PDF]

J Clin Med
Dancs PT, Pohlmann MC, Bednarsch J, Rashidi-Alavijeh J, Schmitz SM, Kroh A, Ulmer F, Vondran FWR, Neumann UP, Hoyer DP, Heise D.   +10 more
europepmc   +1 more source

Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib

British Journal of Clinical Pharmacology, EarlyView.
Aim Small‐molecule activin receptor‐like kinase‐2 inhibitor zilurgisertib (INCB000928) is under investigation in a pivotal trial for the treatment of fibrodysplasia ossificans progressiva (FOP), an ultrarare genetic condition. This analysis assessed effects of renal and hepatic impairment on zilurgisertib pharmacokinetics.
Yan‐ou Yang, Yunlan Fang, Phillip Wang, Xiang Liu, Jay Getsy, Kevin Rockich   +5 more
wiley   +1 more source

Secondary Sclerosing Cholangitis in a Critically Ill Burn Patient: A Case Report and Review of the Literature. [PDF]

Clin Case Rep
Siniora AN, Marouf O, Arekat RR, Abuhilal FA, Salah MI, AbuBaha M, Salameh H, Taha HM.   +7 more
europepmc   +1 more source

Liver homotransplantation [PDF]

, 1977
Putnam, CW, Starzl, TE
core  

A Randomized Controlled Trial Comparing Early Outcomes Following Duct-duct Biliary Anastomosis With or Without Transanastomotic Biliary Stenting in Adult Whole Liver Transplant Patients. [PDF]

Transplant Direct
Byrne SJ, Butler NA, Reiling J, O'Rourke TR, Yeung S, Slater K, Hodgkinson PJ.   +6 more
europepmc   +1 more source

Biliary NF-κB-Inducing Kinase Promotes Ductular Reaction, Inflammation, and Fibrosis and Impedes Liver Disease Resolution. [PDF]

FASEB J
Wang Y, Nikooie R, Kang Q, Rui L.
europepmc   +1 more source